



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: David Eisenberg, M.D., M.P.H.

Committee: Bone, Reproductive, and Urologic Drugs Advisory Committee

Meeting Date: October 30, 2019

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: new drug application (NDA) 204017 (levonorgestrel and ethinyl estradiol) transdermal system, submitted by Agile Therapeutics, Inc., for the prevention of pregnancy in women of reproductive potential, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Consultant/advisor	Medicines360, a competing firm	\$0 – \$2,000
II. Other Imputed Interests		
Contract/grant	Medicines360, a competing firm	\$100,000 – \$150,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

10/11/2019
Date